1. Clinical & Scientific Overview
Fluticasone Furoate (TIP-MED-000359, Reference Code [9.11]-C89) is classified under
Respiratory, Asthma, COPD & Allergy Medicines (Ch 09) as a Potent Topical Glucocorticoid Receptor Agonists — ICS & Intranasal Steroid Sprays (Schedule H | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [9.11] (Fluticasone Propionate & Fluticasone Furoate (Inhaled & Intranasal Corticosteroids)). Representative Indian Market Examples (Edition 2.7 Ch 09 [9.11], p. 119): Inhaled (ICS): Flohale (Cipla), Flixotide; FDCs: Seroflo (Salmeterol+Fluticasone), Formonide-F. Intranasal Spray: Flomist (Cipla — Propionate 50 mcg), Avamys / Nezaflo (Furoate 27.5 mcg) — Strengths & Dosage Forms: Inhaled pMDI: 50, 125, 250 mcg/puff; Rotacaps: 100, 250, 500 mcg; Respules: 0.5 mg/2mL. Aqueous Nasal Spray: Fluticasone Propionate 50 mcg/spray; Fluticasone Furoate 27.5 mcg/spray
Inhaled pMDI: 50, 125, 250 mcg/puff; Rotacaps: 100, 250, 500 mcg; Respules: 0.5 mg/2mL. Aqueous Nasal Spray: Fluticasone Propionate 50 mcg/spray; Fluticasone Furoate 27.5 mcg/spray
3. Mechanism of Action & Pharmacodynamics
Potent Topical Glucocorticoid Receptor Agonists — ICS & Intranasal Steroid Sprays (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Respiratory, Asthma, COPD & Allergy Medicines (Ch 09): clinical efficacy is mediated via Potent Topical Glucocorticoid Receptor Agonists — ICS & Intranasal Steroid Sprays (Schedule H | NLEM 2022) for Inhaled (ICS): Maintenance anti-inflammatory controller therapy for bronchial asthma and severe COPD with frequent exacerbations/eosinophilia. Intranasal Spray: First-line controller treatment for moderate-to-severe seasonal & perennial Allergic Rhinitis and nasal polyps.
4. Therapeutic Indications & Evidence-Supported Uses
- Inhaled (ICS): Maintenance anti-inflammatory controller therapy for bronchial asthma and severe COPD with frequent exacerbations/eosinophilia
- Intranasal Spray: First-line controller treatment for moderate-to-severe seasonal & perennial Allergic Rhinitis and nasal polyps
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Inhaled Asthma Controller (Adults): Low: 100–250 mcg/d; Medium: >250–500 mcg/d; High: >500–1000 mcg/d (BD). Intranasal Allergic Rhinitis: Fluticasone Propionate (Flomist): 2 sprays/nostril OD (200 mcg/d); Fluticasone Furoate (Avamys): 2 sprays/nostril OD (110 mcg/d), stepping down to 1 spray/nostril OD
Administration & Meal Timing: INHALED ICS: Always use a spacer with pMDI and RINSE MOUTH, GARGLE, & SPIT OUT WATER immediately after every inhalation! INTRANASAL SPRAY: Aim nozzle SLIGHTLY OUTWARDS away from the central nasal septum ('Right hand for Left nostril, Left hand for Right nostril') to prevent epistaxis! | Inhaled: Morning & Evening (BD). Nasal Spray: Morning (Once Daily)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [9.11].
Renal: No adjustment needed. Hepatic: Plasma levels increase in severe cirrhosis
Renal: No adjustment needed. Hepatic: Plasma levels increase in severe cirrhosis
Renal: No adjustment needed. Hepatic: Plasma levels increase in severe cirrhosis
7. Contraindications, Precautions & High-Risk Warnings
- Inhaled ICS is NEVER for acute asthma rescue! Contraindicated in untreated nasal/pulmonary tuberculosis. High-dose inhaled Fluticasone (>500–1000 mcg/d) in COPD carries an increased risk of pneumonia!
Key Clinical Precautions: Renal: No adjustment needed. Hepatic: Plasma levels increase in severe cirrhosis
8. Adverse Effects Profile
- Inhaled: Oral candidiasis (thrush — 5–10% if mouth rinse omitted), hoarseness/dysphonia. Nasal Spray: Mild epistaxis (if sprayed onto central septum!), nasal dryness
- Iatrogenic Cushing's syndrome and secondary adrenal crisis (especially if combined with CYP3A4 inhibitors!), pneumonia in COPD, growth velocity reduction in children, glaucoma/cataracts
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL CYP3A4 INHIBITOR INTERACTION: Fluticasone undergoes 99% hepatic CYP3A4 first-pass inactivation — Ritonavir, Cobicistat, Itraconazole, Ketoconazole, and Clarithromycin block CYP3A4 and increase systemic Fluticasone levels by >100-fold, causing severe Cushing's syndrome and adrenal suppression even from a nasal spray or inhaler!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [9.11].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: FOR INHALER: Rinse mouth and spit after every puff; FOR NASAL SPRAY (Flomist/Avamys): Aim nozzle slightly outwards towards the outer eye (never straight at the middle wall of the nose!), sniff gently, and use daily for at least 3–5 days for full allergy relief
- Meal & Clock Timing Instruction: INHALED ICS: Always use a spacer with pMDI and RINSE MOUTH, GARGLE, & SPIT OUT WATER immediately after every inhalation! INTRANASAL SPRAY: Aim nozzle SLIGHTLY OUTWARDS away from the central nasal septum ('Right hand for Left nostril, Left hand for Right nostril') to prevent epistaxis! (Inhaled: Morning & Evening (BD). Nasal Spray: Morning (Once Daily))
- Missed Dose Protocol: Take as soon as remembered; use daily even when symptom-free
- Geriatric Dispensing Pearl: In older COPD patients, use the lowest effective ICS dose to minimise pneumonia and fracture risk
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Inhaled pMDI: 50, 125, 250 mcg/puff; Rotacaps: 100, 250, 500 mcg; Respules: 0.5 mg/2mL. Aqueous Nasal Spray: Fluticasone Propionate 50 mcg/spray; Fluticasone Furoate 27.5 mcg/spray
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [9.9] Levocetirizine, Cetirizine & Chlorpheniramine Maleate (Oral H1 Antihistamines) — Histamine H1-Receptor Inverse Agonists (Second-Generation Non-Sed
- [9.10] Levosalbutamol (Levalbuterol) — Single R-Enantiomer Selective Beta-2 Adrenoceptor Agonist Broncho
- [9.11] Fluticasone Propionate & Fluticasone Furoate (Inhaled & Intranasal Corticosteroids) — Potent Topical Glucocorticoid Receptor Agonists — ICS & Intranasa
- [9.12] Beclomethasone Dipropionate (Alone & in Formoterol / Levosalbutamol Inhalers) — Inhaled Corticosteroid (ICS) Prodrug Activated by Pulmonary Ester
